The US drugmaker Eli Lilly has bowed to demands from Donald Trump by raising the prices of its weight-loss jab for UK ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

Healthcare technology company Philips announced that it is investing more than $150 million in U.S. manufacturing and ...

Eli Lilly has signed a deal worth up to $1.3 billion with privately held Superluminal Medicines to discover and develop drugs ...

Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

Clinicians should ask patients if they’re experiencing ‘diabetes device distress’ and help guide them through it.

By Nqobile Dludla and Siyanda Mthethwa JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug ...

Eli Lilly has been accused of giving illegal inducements to encourage medical providers in Texas to prescribe its medicines ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

(Reuters) -More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein ...